StemRIM Inc. Logo

StemRIM Inc.

Developing regenerative medicines that use the body's own stem cells to treat intractable diseases.

4599 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
茨木市彩都あさぎ7丁目7番15号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

StemRIM Inc. is a biotechnology company engaged in the research and development of a next-generation class of regenerative medicine called "Regeneration-Inducing Medicine™". Originating as a venture from Osaka University, the company focuses on developing drugs with a novel mechanism of action. This approach aims to maximize the body's innate ability to repair itself by recruiting a patient's own in-vivo stem cells to damaged tissues, thereby inducing functional regeneration without conventional cell-therapy. The company's drug development pipelines target intractable diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-12 05:32
Regulatory News Service
訂正臨時報告書
Japanese 30.7 KB
2025-03-13 04:31
Report Publication Announcement
確認書
Japanese 8.0 KB
2025-03-13 04:30
Interim Report
半期報告書-第20期(2024/08/01-2025/07/31)
Japanese 228.6 KB
2024-11-25 08:13
Registration Form
有価証券届出書(参照方式)
Japanese 49.5 KB
2024-11-18 01:31
Share Issue/Capital Change
訂正臨時報告書
Japanese 32.6 KB
2024-11-13 08:10
Regulatory News Service
臨時報告書
Japanese 36.2 KB
2024-10-31 05:28
Post-Annual General Meeting Information
臨時報告書
Japanese 22.4 KB
2024-10-31 03:35
Governance Information
内部統制報告書-第19期(2023/08/01-2024/07/31)
Japanese 21.0 KB
2024-10-31 03:35
Registration Form
確認書
Japanese 8.1 KB
2024-10-31 03:32
Annual Report
有価証券報告書-第19期(2023/08/01-2024/07/31)
Japanese 2.7 MB
2024-07-26 08:53
Regulatory News Service
臨時報告書
Japanese 35.7 KB
2024-07-26 08:53
Regulatory News Service
臨時報告書
Japanese 35.8 KB
2024-07-25 02:46
Regulatory News Service
臨時報告書
Japanese 21.7 KB
2024-06-13 02:57
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-06-13 02:56
Quarterly Report
四半期報告書-第19期第3四半期(2024/02/01-2024/04/30)
Japanese 166.9 KB

Automate Your Workflow. Get a real-time feed of all StemRIM Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for StemRIM Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
WAKAMOTO PHARMACEUTICAL CO.,LTD. Logo
Develops gastrointestinal and ophthalmic drugs for the health challenges of an aging society.
Japan 4512
WELLBIOTEC CO.,LTD Logo
Diversified in biopharma, EV chargers, and lithium supply for batteries.
South Korea 010600
WHANIN PHARM CO.,LTD Logo
Develops and sells pharmaceuticals, specializing in CNS, cardiovascular, and GI drugs.
South Korea 016580
WooGeneB&GCO.,Ltd Logo
Manufactures veterinary medicines, vaccines, and supplements for livestock and aquatic animals.
South Korea 018620
Xbrane Biopharma Logo
Develops affordable biosimilars for serious diseases using patented, high-yield production tech.
Sweden XBRANE
Xintela AB Logo
Develops stem cell therapies for osteoarthritis and venous leg ulcers using proprietary technology.
Sweden XINT
Xspray Pharma Logo
Develops improved cancer drugs (PKIs) using patented tech to circumvent secondary patents.
Sweden XSPRAY
Y.B Urban Renewal - Residential Development LTD Logo Israel CSURE-M
YUHAN CORPORATION Logo
A pharmaceutical & chemical firm developing drugs, supplements, consumer products, and APIs.
South Korea 000100
YUKI GOSEI KOGYO CO.,LTD. Logo
Manufactures fine chemicals, amino acids, and APIs via organic synthesis for global industries.
Japan 4531

Talk to a Data Expert

Have a question? We'll get back to you promptly.